Company news

EyePoint, Inc. news in 2024

EyePoint, Inc.'s news releases, calls and decks from 2024, newest first.

View company

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16, 2024

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

December 3, 2024

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

November 6, 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

November 3, 2024

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

October 30, 2024

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

October 28, 2024

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 27, 2024

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

October 27, 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

October 23, 2024

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

September 3, 2024

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

August 7, 2024

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

August 6, 2024

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

June 25, 2024

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

June 17, 2024

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

May 7, 2024

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

May 5, 2024

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

April 1, 2024

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

March 6, 2024

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

March 3, 2024

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

February 28, 2024

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

February 2, 2024

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

January 30, 2024

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

January 9, 2024

Calls in 2024

Decks in 2024